<DOC>
	<DOCNO>NCT01720264</DOCNO>
	<brief_summary>The main purpose trial ass efficacy safety sitagliptin enhance engraftment follow umbilical cord blood transplantation ( recovery blood count transplant ) .</brief_summary>
	<brief_title>Multicenter Phase II CD26 Using Sitagliptin Engraftment After UBC Transplant</brief_title>
	<detailed_description>Umbilical cord blood ( UCB ) commonly use transplantation child use adult often . However , adult large child , relatively small stem cell dose UCB major limitation transplantation adult engraftment delay . This study try find drug sitagliptin use increase speed engraftment adult receive UCB transplantation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients must one follow disease type : Acute myeloid leukemia ( AML ) disease feature describe protocol . Acute lymphoblastic leukemia ( ALL ) disease feature describe protocol . Myelodysplasia disease feature describe protocol . Chronic myelogenous leukemia ( CML ) disease feature describe protocol . Patients aggressive nonHodgkin 's lymphoma ( NHL ) , include diffuse large cell lymphoma , mediastinal Bcell lymphoma , transform lymphoma , mantle cell lymphoma , peripheral T cell lymphoma , also one disease feature describe protocol . At least 35 day follow start precede leukemia induction cytotoxic chemotherapy . For patient remission , readily available consent HLAmatched related donor either match fully match mismatch one locus HLAA , B , DRB1 . No availability readily available HLAmatched volunteer unrelated donor ( 8 8 allele match HLAA , B , C DRB1 ) . Patients must match partially match UCB unit &gt; /= 2.5 x10^7 nucleate cells/kg recipient weight time cryopreservation . No current uncontrolled bacterial , viral fungal infection ( define currently take medication progression clinical symptom ) . No HIV disease . Non pregnant nonnursing . Required baseline laboratory value describe protocol . Signed write informed consent . Symptomatic uncontrolled coronary artery disease congestive heart failure . Severe hypoxemia room air PaO2 &lt; 70 , supplemental oxygen dependence , DLCO &lt; 50 % predict . Patients central nervous system ( CNS ) involvement refractory intrathecal chemotherapy . Prior allogeneic autologous hematopoietic stem cell transplant last 6 month . Patients take insulin secretagogues and/or insulin . Patients hypersensitivity sitagliptin . Patients history pancreatitis , cholelithiasis , alcoholism , fast hypertriglyceridemia ( &gt; 2 x ULN ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>